Skip to main content
TransThera Sciences (Nanjing), Inc. logo

TransThera Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 2617 ISIN · CNE100006T02 HKEX Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2025-10-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2617

About TransThera Sciences (Nanjing), Inc.

https://www.transthera.com

TransThera Sciences (Nanjing), Inc. is a clinical-stage, R&D-driven biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapies. Established in 2014, the company employs a clinical demand-oriented approach to address diseases with significant unmet medical needs. TransThera's pipeline is dedicated to generating first-in-class, best-in-class, and highly differentiated treatments, primarily targeting therapeutic areas such as oncology, inflammatory diseases, and cardiovascular conditions.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Regulatory Filings Classification · 95% confidence The document is a standardized monthly return (Form FF301) filed by a Hong Kong‐listed issuer under Chapter 19B of the Exchange Listing Rules, detailing movements in authorised/issued share capital, treasury shares and confirmatory statements. It does not present quarterly/annual financial results, nor is it an AGM, dividend notice, earnings release, or investor presentation. It is a regulatory submission required by HKEX but does not fall into any more specific category, so it best fits the fallback “Regulatory Filings” category.
2025-10-03 English
INTERIM REPORT 2025
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled '2025 INTERIM REPORT' and contains comprehensive financial statements (Statement of Profit or Loss, Financial Position, Cash Flows, etc.) for the six-month period ended 30 June 2025. It includes an Independent Review Report by Ernst & Young and detailed notes to the financial information. It meets the criteria for an Interim/Quarterly Report as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-09-19 English
VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS
Regulatory Filings Classification · 88% confidence The document is a voluntary announcement by a Hong Kong listed company about unusual price and trading volume movements. It contains no financial data, report attachments, or meeting materials. It is a regulatory announcement rather than an actual financial report or capital transaction. This fits the fallback category “Regulatory Filings” (RNS) for miscellaneous compliance announcements on the exchange.
2025-09-16 English
VOLUNTARY ANNOUNCEMENT PHASE II IND APPROVAL OF TINENGOTINIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF PREVIOUSLY TREATED HR+/HER2 NEGATIVE OR LOW EXPRESSION RELAPSED OR METASTATIC BRE
Regulatory Filings Classification · 82% confidence The document is a voluntary announcement by TransThera Sciences (Nanjing), Inc. regarding the IND approval for a Phase II clinical trial of its drug combination. It does not present financial results, regulatory thresholds of shareholding, or notice of a meeting; nor is it an annual or interim report, earnings release, dividend notice, or other specific category. It is a general corporate update/notification of a regulatory milestone and falls under the miscellaneous regulatory announcements. Therefore, it is classified as a Regulatory Filing (RNS).
2025-09-10 English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH AKESO'S (CADONILIMAB, PD-1/CTLA-4) / (IVONESCIMAB, PD-1/VEGF)
Regulatory Filings Classification · 75% confidence The document is a short voluntary announcement by TransThera Sciences announcing the dosing of the first patient in a Phase II clinical trial. It does not present any financial results or attach a report nor request votes. It is not an earnings release (no financial highlights), not a board or management change, and not a capital or share transaction. It simply informs investors of a corporate development and falls under a general regulatory announcement. Therefore, it is classified as a Regulatory Filing (RNS).
2025-09-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025
Regulatory Filings Classification · 85% confidence The document is Form FF301, a routine monthly return filed to the Hong Kong Stock Exchange detailing movements in authorised/registered share capital and issued shares under Chapter 19B of the Listing Rules. It is not an earnings release, proxy statement, or specific capital issuance notice but rather a regulatory submission of share capital movements. As there is no specific category for a monthly return in our taxonomy, it falls into the general Regulatory Filings category. Therefore, we classify it as RNS.
2025-09-02 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.